Monopar Therapeutics (NASDAQ:MNPR) Given New $22.00 Price Target at HC Wainwright

Monopar Therapeutics (NASDAQ:MNPR) had its target price boosted by HC Wainwright from $6.00 to $22.00 in a research report sent to investors on Monday morning,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Monopar Therapeutics’ Q4 2024 earnings at ($0.34) EPS, FY2024 earnings at ($1.68) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.40) EPS and FY2025 earnings at ($1.48) EPS.

Separately, Rodman & Renshaw initiated coverage on shares of Monopar Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $50.00 price target on the stock.

Monopar Therapeutics Trading Down 5.2 %

Monopar Therapeutics stock opened at $18.23 on Monday. The firm has a market capitalization of $96.25 million, a PE ratio of -9.25 and a beta of 1.09. Monopar Therapeutics has a 1-year low of $1.37 and a 1-year high of $38.50. The firm’s 50 day simple moving average is $8.79 and its 200 day simple moving average is $5.19.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09. Research analysts forecast that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Insider Buying and Selling

In other Monopar Therapeutics news, CFO Karthik Radhakrishnan bought 1,550 shares of Monopar Therapeutics stock in a transaction dated Monday, October 28th. The shares were purchased at an average cost of $16.25 per share, with a total value of $25,187.50. Following the completion of the purchase, the chief financial officer now owns 1,550 shares of the company’s stock, valued at approximately $25,187.50. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 34.90% of the stock is owned by corporate insiders.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.